Literature DB >> 22306293

Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase.

Xueliang Gao1, Haizhen Wang, Jenny J Yang, Xiaowei Liu, Zhi-Ren Liu.   

Abstract

Pyruvate kinase isoform M2 (PKM2) is a glycolysis enzyme catalyzing conversion of phosphoenolpyruvate (PEP) to pyruvate by transferring a phosphate from PEP to ADP. We report here that PKM2 localizes to the cell nucleus. The levels of nuclear PKM2 correlate with cell proliferation. PKM2 activates transcription of MEK5 by phosphorylating stat3 at Y705. In vitro phosphorylation assays show that PKM2 is a protein kinase using PEP as a phosphate donor. ADP competes with the protein substrate binding, indicating that the substrate may bind to the ADP site of PKM2. Our experiments suggest that PKM2 dimer is an active protein kinase, while the tetramer is an active pyruvate kinase. Expression of a PKM2 mutant that exists as a dimer promotes cell proliferation, indicating that protein kinase activity of PKM2 plays a role in promoting cell proliferation. Our study reveals an important link between metabolism alteration and gene expression during tumor transformation and progression. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22306293      PMCID: PMC3299833          DOI: 10.1016/j.molcel.2012.01.001

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  42 in total

1.  Effects of glucose and amino acids on free ADP in betaHC9 insulin-secreting cells.

Authors:  P Ronner; C M Naumann; E Friel
Journal:  Diabetes       Date:  2001-02       Impact factor: 9.461

2.  Interaction between HERC1 and M2-type pyruvate kinase.

Authors:  Francesc R Garcia-Gonzalo; Cristina Cruz; Purificación Muñoz; Sybille Mazurek; Erich Eigenbrodt; Francesc Ventura; Ramon Bartrons; Jose Luis Rosa
Journal:  FEBS Lett       Date:  2003-03-27       Impact factor: 4.124

3.  The tumor metabolome.

Authors:  Sybille Mazurek; Erich Eigenbrodt
Journal:  Anticancer Res       Date:  2003 Mar-Apr       Impact factor: 2.480

4.  Isozymes of pyruvate kinase from human brain, meningiomas, and malignant gliomas.

Authors:  C W van Veelen; H Verbiest; A M Vlug; G Rijksen; G E Staal
Journal:  Cancer Res       Date:  1978-12       Impact factor: 12.701

5.  Measurement of the ADP:ATP ratio in human leukaemic cell lines can be used as an indicator of cell viability, necrosis and apoptosis.

Authors:  D A Bradbury; T D Simmons; K J Slater; S P Crouch
Journal:  J Immunol Methods       Date:  2000-06-23       Impact factor: 2.303

6.  The dual activity of pyruvate kinase type M2 from chromatin extracts of neoplastic cells.

Authors:  Jan Ignacak; Maria Barbara Stachurska
Journal:  Comp Biochem Physiol B Biochem Mol Biol       Date:  2003-03       Impact factor: 2.231

7.  Tumor M2-pyruvate kinase in lung cancer patients: immunohistochemical detection and disease monitoring.

Authors:  Joachim Schneider; Kathleen Neu; Helmut Grimm; Hans-Georg Velcovsky; Gunter Weisse; Erich Eigenbrodt
Journal:  Anticancer Res       Date:  2002 Jan-Feb       Impact factor: 2.480

8.  A simple procedure for the synthesis of [32P]phosphoenolpyruvate via the pyruvate kinase exchange reaction at equilibrium.

Authors:  F F Roossien; J Brink; G T Robillard
Journal:  Biochim Biophys Acta       Date:  1983-10-04

9.  Stat3 upregulates MEK5 expression in human breast cancer cells.

Authors:  Hui Song; Xiaohong Jin; Jiayuh Lin
Journal:  Oncogene       Date:  2004-10-28       Impact factor: 9.867

10.  Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation.

Authors:  Weiwei Yang; Yan Xia; Haitao Ji; Yanhua Zheng; Ji Liang; Wenhua Huang; Xiang Gao; Kenneth Aldape; Zhimin Lu
Journal:  Nature       Date:  2011-12-01       Impact factor: 49.962

View more
  314 in total

1.  Pyruvate kinase M knockdown-induced signaling via AMP-activated protein kinase promotes mitochondrial biogenesis, autophagy, and cancer cell survival.

Authors:  Gopinath Prakasam; Rajnish Kumar Singh; Mohammad Askandar Iqbal; Sunil Kumar Saini; Ashu Bhan Tiku; Rameshwar N K Bamezai
Journal:  J Biol Chem       Date:  2017-08-04       Impact factor: 5.157

2.  The transglutaminase type 2 and pyruvate kinase isoenzyme M2 interplay in autophagy regulation.

Authors:  Sara Altuntas; Federica Rossin; Claudia Marsella; Manuela D'Eletto; Laura Diaz-Hidalgo; Maria Grazia Farrace; Michelangelo Campanella; Manuela Antonioli; Gian Maria Fimia; Mauro Piacentini
Journal:  Oncotarget       Date:  2015-12-29

Review 3.  HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations.

Authors:  Gregg L Semenza
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

4.  Synthetic Deletion of the Interleukin 23 Receptor (IL-23R) Stalk Region Led to Autonomous IL-23R Homodimerization and Activation.

Authors:  Thorben M Hummel; Theresa Ackfeld; Marco Schönberg; Gregor Ciupka; Falk Schulz; Anne Oberdoerster; Joachim Grötzinger; Jürgen Scheller; Doreen M Floss
Journal:  Mol Cell Biol       Date:  2017-08-11       Impact factor: 4.272

Review 5.  Pyruvate kinase: Function, regulation and role in cancer.

Authors:  William J Israelsen; Matthew G Vander Heiden
Journal:  Semin Cell Dev Biol       Date:  2015-08-13       Impact factor: 7.727

6.  Pyruvate Kinase Inhibits Proliferation during Postnatal Cerebellar Neurogenesis and Suppresses Medulloblastoma Formation.

Authors:  Katherine Tech; Andrey P Tikunov; Hamza Farooq; A Sorana Morrissy; Jessica Meidinger; Taylor Fish; Sarah C Green; Hedi Liu; Yisu Li; Andrew J Mungall; Richard A Moore; Yussanne Ma; Steven J M Jones; Marco A Marra; Matthew G Vander Heiden; Michael D Taylor; Jeffrey M Macdonald; Timothy R Gershon
Journal:  Cancer Res       Date:  2017-05-17       Impact factor: 12.701

7.  Pyruvate kinase isoform expression alters nucleotide synthesis to impact cell proliferation.

Authors:  Sophia Y Lunt; Vinayak Muralidhar; Aaron M Hosios; William J Israelsen; Dan Y Gui; Lauren Newhouse; Martin Ogrodzinski; Vivian Hecht; Kali Xu; Paula N Marín Acevedo; Daniel P Hollern; Gary Bellinger; Talya L Dayton; Stefan Christen; Ilaria Elia; Anh T Dinh; Gregory Stephanopoulos; Scott R Manalis; Michael B Yaffe; Eran R Andrechek; Sarah-Maria Fendt; Matthew G Vander Heiden
Journal:  Mol Cell       Date:  2014-12-04       Impact factor: 17.970

8.  PK-M2-mediated metabolic changes in breast cancer cells induced by ionizing radiation.

Authors:  Le Zhang; Justine Bailleul; Taha Yazal; Kevin Dong; David Sung; Amy Dao; Laura Gosa; David Nathanson; Kruttika Bhat; Sara Duhachek-Muggy; Claudia Alli; Milana Bochkur Dratver; Frank Pajonk; Erina Vlashi
Journal:  Breast Cancer Res Treat       Date:  2019-08-01       Impact factor: 4.872

9.  Loss of abhd5 promotes colorectal tumor development and progression by inducing aerobic glycolysis and epithelial-mesenchymal transition.

Authors:  Juanjuan Ou; Hongming Miao; Yinyan Ma; Feng Guo; Jia Deng; Xing Wei; Jie Zhou; Ganfeng Xie; Hang Shi; Bingzhong Xue; Houjie Liang; Liqing Yu
Journal:  Cell Rep       Date:  2014-12-04       Impact factor: 9.423

10.  PKM2 inhibitor shikonin suppresses TPA-induced mitochondrial malfunction and proliferation of skin epidermal JB6 cells.

Authors:  Wenjuan Li; Joan Liu; Yunfeng Zhao
Journal:  Mol Carcinog       Date:  2012-12-19       Impact factor: 4.784

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.